Slide 1: Investor Presentation September 2011
Investor Presentation September 2011
Slide 2: Disclaimer
DISCLAIMER Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Agenda
AGENDA BIOCON SNAPSHOT PRODUCTS (BRANDED FORMULATIONS) RESEARCH & DEVELOPMENT STRATEGIC ALLIANCES FINANCIAL HIGHLIGHTS 3
Slide 4: Biocon Snapshot
BIOCON SNAPSHOT gS Biocon
Slide 5: Vision
VISION Biocon is an emerging, global Bio-pharmaceutical enterprise that is focused on developing affordable products and services for patients, partners and healthcare systems across the world. Biocon is committed to: • Reducing therapy costs of chronic diseases. (Diabetes, cancer and immune-mediate
Slide 6: Business Structure & Holdings
BUSINESS STRUCTURE & HOLDINGS 61% | Promoters ~5 % | Employees & ESOP trust Syngene International Ltd, India | 100% Custom research, drug discovery ~34 % | Public Biocon Clinigene International Ltd, India | 100% Clinical development Biocon Research, India | 100% R&D- Novel Molecules Biocon Biopharma
Slide 7: A Differentiated Business Model
A DIFFERENTIATED BUSINESS MODEL BALANCED PORTFOLIO : Products & Services ~ 23% Revenue SELF-FINANCED R&D CAGR and AND MANUFACTURING PRODUCTS STRATEGIC RESEARCH & ~ 17% MARKETING PARTNERSHIPS EBITDA CAGR RISK-BALANCED R&D PIPELINE: (excluding RESEARCH Axicorp) SERVICES Biosimilars & Novels Over the p
Slide 8: Product Portfolio: Verticals
PRODUCT PORTFOLIO: VERTICALS New Molecules New chemistry- oriented molecules Biologics MAbs, IN-105, Itolizumab Other novel Small Molecules biologics Research Services Statins, Fidaxomicin, Syngene Immunosuppressants Clinigene Insulin Other Bio-pharma Insulin & analogs Orlistat & Other APIs Branded
Slide 9: Research Services
RESEARCH SERVICES gS DISCOVERY SERVICES CLINICAL RESEARCH CLIENTS CLIENTS Large & mid-size Pharma & Biotech Companies On-going collaboration with over Syngene 60 companies worldwide Large & mid-size Pharma & Biotech Companies SERVICES Clinical Operations & Development Biology R&D Clinigene Clinical
Slide 10: Global Scale Manufacturing Base
GLOBAL SCALE MANUFACTURING BASE 10
Slide 11: Products (Branded Formulations)
PRODUCTS (BRANDED FORMULATIONS)
Slide 12: Products & Markets
PRODUCTS & MARKETS $ Bi EUROPE, USA, LATIN AMERICA SOUTH EAST ASIA & THE MIDDLE EAST 12
Slide 13: Therapeutics Segments (India)
THERAPEUTICS SEGMENTS (INDIA) 13
Slide 14: Biocon's Insulin Business (India)
BIOCON’S INSULIN BUSINESS (INDIA) The 2007-2010 CAGR Biocon’s ranking Biocon’s market share by figures for unit sales of volume: Insulin 40 IU: #20 in the OAD market Market: 11% rh-Insulin: 11% #3 in the rhe-Insulin market Biocon: 13% Glargine: 13% #2 in the Glargine market NN: 9% Source : IMS HEALT
Slide 15: Research & Development
Research & Development
Slide 16: High Potential Product Pipeline
HIGH POTENTIAL PRODUCT PIPELINE Diabetes IN 105 Oncology / Inflammation / ItolizuMAb Auto immune Novel Molecules Oncology Anti-EGFR Oncology Anti-CD 20 Diabetes Peptide Hybrid Targeted Oncology Immunoconjugates Oncology/Immunology Biosimilar MAbs Biosimilars Diabetes Insulin & Analogues rHrHInsulin,
Slide 17: Lead Program: Oral Insulin IN-105
LEAD PROGRAM: ORAL INSULIN IN-105 Drug Highlights Conjugated peptide Lower immunogenicity and mitogenicity. Comparable safety and good clearance profile. Metabolically equivalent. Monotherapy. Combination therapy with metformin, sulfonylurea, PPAR agonists, DPP4i. Pre-meal insulin in combination wit
Slide 18: IN-105 India Phase III Result Summary
IN-105 INDIA PHASE III RESULT SUMMARY SECONDARY END POINTS Efficacy – Secondary Endpoints Statistically significant reduction in PPG during STM Significant reduction in SMBG post prandial glucose excursion Safety – Secondary Endpoints No clinically significant hypoglycemia Very low immunogenic
Slide 19: Anti-CD6 MAb: T1h
ANTI-CD6 MAb: T1h Drug Highlights Target CD6 o.4mg/kg once in 4 weeks is a type 1 cell membrane glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) super family group B. CD6 is predominantly expressed by T cells & a B cell subset. Day 1 Day 29 CD6 binds ALCAM (activated leukocyte c
Slide 20: Strategic Alliances
$ Biocon STRATEGIC ALLIANCES
Slide 21: Strategic Research Partnerships
STRATEGIC RESEARCH PARTNERSHIPS NOVEL PEPTIDE Amylin Diabetes INTEGRATED DD SERVICES BMS Discovery to commercialization IMMUNOCONJUGATED MAbs IATRICa Oncology BIOSIMILARS Mylan Oncology, Auto-Immune Diseases NOVEL APIs Optimer First-in-class anti-infective (C.difficile) BIOSIMILARS Pfizer Diabetes B
Slide 22: Biosimilars Partnership: Pfizer
BIOSIMILARS PARTNERSHIP: PFIZER Insulin and Insulin analogs Combines Biocon's research and manufacturing capabilities with Pfizer's global marketing prowess Global agreement for the Pfizer will have exclusive Biocon will be commercialization of Biocon's rights (with some responsible for clinical bio
Slide 23: Global Insulin Market (2010)
GLOBAL INSULIN MARKET (2010) Total 2010 Insulin Market USD ~15 bn ~ USD 20 bn in 2020 Growth forecast of ~6% per annum* *Factoring the advent of Biosimilar Insulins Sources: Biocon’s estimates complied from Industry reports 23
Slide 24: Biosimilars Partnership: Mylan
BIOSIMILARS PARTNERSHIP: MYLAN Monoclonal Antibodies (MAbs) Combines Biocon's R&D and manufacturing of novel biologics/bio-generics with Mylan’s regulatory and commercialization capabilities in the US and Europe Exclusive Collaboration is for a Mylan will have Biocon and Mylan collaboration for bask
Slide 25: Financial Highlights
FINANCIAL HIGHLIGHTS gS Biocon
Slide 26: Top & Bottom Line
TOP & BOTTOM LINE INR crore / USD mn FY08 FY09 FY10 FY11 Revenue 1090 273 1673 364 2405 512 2814 616 EBITDA 335 83 388 84 509 108 630 138 Net profit* 225 56 240 52 293 62 368 80 FY08-11: Avg.exch.rate in that fiscal Q1 FY12: USD 1 = INR 45 * Net profit is pre-exceptional in table 1 No exceptional it
Slide 27: Revenue Mix: Segment Wise
REVENUE MIX: SEGMENT WISE Total Revenues (excluding Axicorp) FY11: INR 1844 Cr. Statins 30% Insulins & Immunosuppressants Research 18% Services 20% Branded Biocon+ BBPL + BRL formulations 80% 10% Licensing Income Other Biopharma 5% 17% Approximate percentages as of 30 June 2011 27
Slide 28: Thank You
Thank You